 |
 |
Development of VALCHLOR™, a topically delivered cytotoxic agent to treat cutaneous T-cell lymphoma (CTCL). |
Ceptaris Therapeutics, Inc
Malvern, PA
www.ceptaris.com
|
|
 |
Molecular imaging agent uses manganese to enhance functional imaging with MRI in cardiology and oncology applications. |
Eagle Vision Pharmaceutical Corp.
Exton, PA
www.eaglevpc.com
|
|
 |
Total joint resurfacing technology based on a proprietary synthetic cartilage. BioAdvance exited through a refinancing in 2011. |
Formae, Inc.
Paoli, PA
kmansmann@msn.com
|
|
 |
Innovative breathing control medicines for acute and chronic neurorespiratory conditions, including opiate-induced respiratory depression and sleep apnea. |
Galleon Pharmaceuticals, LLC
Horsham, PA
www.galleonpharma.com
|
|
 |
Proprietary native Human Monoclonal Antibody (N-huMAb) platform which enables the discovery of N-huMAbs engineered by the human immune system that are not accessible by other antibody cloning methods. |
Immunome, Inc. Wynnewood, PA
www.immunomeinc.com
|
|
 |
The Infrascanner™ handheld imaging device uses near infrared light to screen for intracranial bleeding in patients with head trauma. The product has received a CE mark in 2008 and 510(k) clearance in December 2011. |
InfraScan, Inc.
Philadelphia, PA
www.infrascanner.com
|
|
 |
Developing peripherally restricted CB1 antagonist compounds to treat metabolic diseases. |
Jenrin Discovery, Inc.
www.jenrindiscovery.com
|
|
 |
Next generation diagnostic sensor platform to detect RNA, DNA and proteins sample amounts in femtogram/ml range in unpurified liquid samples without the need for incubation, amplification or other special preparation.
|
Leversense, LLC
Newtown Square, PA
www.leversense.com
|
|
 |
Developing clinical-stage compounds in oncology and oncology supportive care, including Lu-AMBA, a targeted radiotherapeutic for treatment of hormone-resistant prostate cancer ,and Pilobuc™, a proprietary buccal formulation of pilocarpine for the treatment of dry mouth. |
Marillion Pharmaceuticals, Inc.
Malvern, PA
www.marillionpharma.com
|
|
 |
Unique theraTRACE® indications discovery platform of over 40 multiplexed in vivo models to identify new therapeutic indications for pre-clinical and development-stage pharmaceuticals. Lead program MLR-1023 being developed to treat diabetes (IND cleared). |
Melior Discovery, Inc.
Exton, PA
www.meliordiscovery.com
|
|
 |
Non-absorbable, oral high molecular weight polyethylene glycol functions as a gut barrier protectant by targeting epithelial cell lipid rafts, inhibiting the pathogenic effects of gut bacteria without exerting antibiotic effects. |
Midway Pharmaceuticals, Inc.
Spring House, PA
www.midwaypharma.com
|
|
 |
Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. Niiki Pharma's lead product, NKP-1339 is a first-in-class small molecule that targets the GRP78 pathway. GRP78 is a master regulator of stress and plays a key role in tumor cell survival and resistance. NKP-1339 is close to completing its Phase I trial, with several patients exhibiting long term anti-tumor activity (stable disease or tumor regression). Niiki Pharma's second product, NKP-2235 is a first-in-class oral small molecule which targets the endoplasmic reticulum. Endoplasmic reticulum is the cell machinery that repairs protein misfolding. NKP-2235 obtained its FDA IND approval in 2011. A Phase I clinical trial of NKP-2335 will begin shortly.
|
Niiki Pharma Inc.
Philadelphia PA and Hoboken, NJ
www.niikipharma.com
|
|
 |
First-in-class antiviral therapeutics based on a novel mechanism of action that targets viral capsid assembly, with initial programs in HIV and HBV. |
Novira Therapeutics, Inc.
Philadelphia, PA
www.noviratherapeutics.com
|
|
 |
NuPathe Inc. Zelrix™ transdermal patch to treat migraine headaches. IPO (NASDAQ: PATH) completed in August 2010. |
NuPathe Inc.
Conshohocken, PA
www.nupathe.com
|
|
.jpg) |
Optofluidics, Inc. Developing microfluidic and biophotonic devices for single molecule manipulation for analysis and point of care medical diagnostics. |
Optofluidics, Inc.
www.optofluidicscorp.com
|
|
 |
Proprietary, high-performance, nanospray systems and consumables for mass spectrometry applications which reduce the sample volume necessary for use in the analyses of proteins, sera and drug-candidate molecules. |
Phoenix S&T
Chester, PA
www.phoenix-st.com
|
|
 |
Developing two novel clinical-stage compounds for the treatment of Alzheimer's disease and Parkinson's disease; Posiphen, which inhibits amyloid precursor protein, and bisnorcymserine, which inhibits butyl cholinesterase. |
QR Pharma Inc
Malvern, PA
www.QRPharma.com
|
|
 |
is developing new products for the treatment of acute and chronic pain. |
Relmada Therapeutics, Inc.
Bluebell, PA
www.relmada.com
|
|
 |
Discovering disease-modifying small molecule compounds that prevent the protein misfolding and aggregation seen in Alzheimer's disease and other neurological conditions. |
Treventis Corporation
Bryn Mawr, PA
www.treventis.com
|
|
.jpg)
.jpg)
© Copyright 2008. BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania. All Rights Reserved.